Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 114

1.

Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms.

Gugliotta L, Iurlo A, Gugliotta G, Tieghi A, Specchia G, Gaidano G, Scalzulli PR, Rumi E, Dragani A, Martinelli V, Santoro C, Randi ML, Tagariello G, Candoni A, Cattaneo D, Ricco A, Palmieri R, Liberati MA, Langella M, Rago A, Bergamaschi M, Monari P, Miglio R, Santoro U, Cacciola R, Rupoli S, Mastrullo L, Musto P, Mazzucconi MG, Vignetti M, Cortelezzi A, Vianelli N, Martino B, Stefano V, Passamonti F, Vannucchi AM; Registro Italiano Trombocitemie RIT.

Leuk Res. 2016 Apr 7;46:18-25. doi: 10.1016/j.leukres.2016.04.004. [Epub ahead of print]

PMID:
27107744
2.

Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group.

Rotunno G, Pacilli A, Artusi V, Rumi E, Maffioli M, Delaini F, Brogi G, Fanelli T, Pancrazzi A, Pietra D, Bernardis I, Belotti C, Pieri L, Sant'Antonio E, Salmoiraghi S, Cilloni D, Rambaldi A, Passamonti F, Barbui T, Manfredini R, Cazzola M, Tagliafico E, Vannucchi AM, Guglielmelli P.

Am J Hematol. 2016 Apr 2. doi: 10.1002/ajh.24377. [Epub ahead of print]

PMID:
27037840
3.

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.

Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Finazzi G, Carobbio A, Thiele J, Passamonti F, Falcone C, Tefferi A.

Blood Cancer J. 2015 Nov 27;5:e369. doi: 10.1038/bcj.2015.94. No abstract available.

4.

Germline RBBP6 mutations in familial myeloproliferative neoplasms.

Harutyunyan AS, Giambruno R, Krendl C, Stukalov A, Klampfl T, Berg T, Chen D, Milosevic Feenstra JD, Jäger R, Gisslinger B, Gisslinger H, Rumi E, Passamonti F, Pietra D, Müller AC, Parapatics K, Breitwieser FP, Herrmann R, Colinge J, Bennett KL, Superti-Furga G, Cazzola M, Hammond E, Kralovics R.

Blood. 2016 Jan 21;127(3):362-5. doi: 10.1182/blood-2015-09-668673. Epub 2015 Nov 16. No abstract available.

PMID:
26574608
5.

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.

Pietra D, Rumi E, Ferretti VV, Buduo CA, Milanesi C, Cavalloni C, Sant'Antonio E, Abbonante V, Moccia F, Casetti IC, Bellini M, Renna MC, Roncoroni E, Fugazza E, Astori C, Boveri E, Rosti V, Barosi G, Balduini A, Cazzola M.

Leukemia. 2016 Feb;30(2):431-8. doi: 10.1038/leu.2015.277. Epub 2015 Oct 9.

6.

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.

Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, Bagienski K, Kubesova B, Pietra D, Gisslinger B, Milanesi C, Jäger R, Chen D, Berg T, Schalling M, Schuster M, Bock C, Constantinescu SN, Cazzola M, Kralovics R.

Blood. 2016 Jan 21;127(3):325-32. doi: 10.1182/blood-2015-07-661835. Epub 2015 Sep 30.

7.

Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia.

Rumi E, Bertozzi I, Casetti IC, Roncoroni E, Cavalloni C, Bellini M, Sant'Antonio E, Gotti M, Ferretti VV, Milanesi C, Peroni E, Pietra D, Astori C, Randi ML, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Haematologica. 2015 Nov;100(11):e443-5. doi: 10.3324/haematol.2015.131458. Epub 2015 Aug 6. No abstract available.

8.

Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.

Rumi E, Milosevic JD, Selleslag D, Casetti I, Lierman E, Pietra D, Cavalloni C, Bellini M, Milanesi C, Dambruoso I, Astori C, Kralovics R, Vandenberghe P, Cazzola M.

Ann Hematol. 2015 Nov;94(11):1927-8. doi: 10.1007/s00277-015-2451-7. Epub 2015 Jul 23. No abstract available.

PMID:
26202607
9.

Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis.

Barbui T, Vannucchi AM, Carobbio A, Thiele J, Rumi E, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Pieri L, Pardanani A, Passamonti F, Finazzi G, Tefferi A.

Am J Hematol. 2015 May;90(5):434-7. doi: 10.1002/ajh.23970. Epub 2015 Feb 27.

10.

Allelic imbalance in CALR somatic mutagenesis.

Harutyunyan AS, Jäger R, Chen D, Berg T, Rumi E, Gisslinger B, Pietra D, Gisslinger H, Cazzola M, Kralovics R.

Leukemia. 2015 Jun;29(6):1431-5. doi: 10.1038/leu.2015.3. Epub 2015 Jan 8. No abstract available.

11.

Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.

Malcovati L, Rumi E, Cazzola M.

Haematologica. 2014 Nov;99(11):1650-2. doi: 10.3324/haematol.2014.113944. No abstract available.

12.

In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology.

Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Gisslinger B, Pieri L, Bertozzi I, Casetti I, Pardanani A, Passamonti F, Vannucchi AM, Tefferi A.

Blood. 2014 Nov 6;124(19):3021-3. doi: 10.1182/blood-2014-07-591610. No abstract available.

13.

Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms.

Jäger R, Harutyunyan AS, Rumi E, Pietra D, Berg T, Olcaydu D, Houlston RS, Cazzola M, Kralovics R.

Am J Hematol. 2014 Dec;89(12):1107-10. doi: 10.1002/ajh.23842. Epub 2014 Sep 26.

14.

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.

Lussana F, Carobbio A, Randi ML, Elena C, Rumi E, Finazzi G, Bertozzi I, Pieri L, Ruggeri M, Palandri F, Polverelli N, Elli E, Tieghi A, Iurlo A, Ruella M, Cazzola M, Rambaldi A, Vannucchi AM, Barbui T.

Br J Haematol. 2014 Nov;167(4):541-6. doi: 10.1111/bjh.13080. Epub 2014 Aug 16.

PMID:
25130523
15.

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.

Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, Sant'Antonio E, Bellini M, Cavalloni C, Mannarelli C, Milanesi C, Boveri E, Ferretti V, Astori C, Rosti V, Cervantes F, Barosi G, Vannucchi AM, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Blood. 2014 Aug 14;124(7):1062-9. doi: 10.1182/blood-2014-05-578435. Epub 2014 Jul 1.

16.

Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases.

Dentali F, Ageno W, Rumi E, Casetti I, Poli D, Scoditti U, Maffioli M, di Minno MN, Caramazza D, Pietra D, De Stefano V, Passamonti F.

Thromb Res. 2014 Jul;134(1):41-3. doi: 10.1016/j.thromres.2014.03.040. Epub 2014 Mar 29.

PMID:
24787989
17.

Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations.

Pennucci V, Zini R, Norfo R, Guglielmelli P, Bianchi E, Salati S, Sacchi G, Prudente Z, Tenedini E, Ruberti S, Paoli C, Fanelli T, Mannarelli C, Tagliafico E, Ferrari S, Vannucchi AM, Manfredini R; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators.

Leuk Lymphoma. 2015 Feb;56(2):492-6. doi: 10.3109/10428194.2014.910661. Epub 2014 Jun 16. No abstract available.

PMID:
24707949
18.

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis.

Rumi E, Harutyunyan AS, Pietra D, Milosevic JD, Casetti IC, Bellini M, Them NC, Cavalloni C, Ferretti VV, Milanesi C, Berg T, Sant'Antonio E, Boveri E, Pascutto C, Astori C, Kralovics R, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Blood. 2014 Apr 10;123(15):2416-9. doi: 10.1182/blood-2014-01-550434. Epub 2014 Feb 19.

19.

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.

Guglielmelli P, Lasho TL, Rotunno G, Score J, Mannarelli C, Pancrazzi A, Biamonte F, Pardanani A, Zoi K, Reiter A, Duncombe A, Fanelli T, Pietra D, Rumi E, Finke C, Gangat N, Ketterling RP, Knudson RA, Hanson CA, Bosi A, Pereira A, Manfredini R, Cervantes F, Barosi G, Cazzola M, Cross NC, Vannucchi AM, Tefferi A.

Leukemia. 2014 Sep;28(9):1804-10. doi: 10.1038/leu.2014.76. Epub 2014 Feb 19.

PMID:
24549259
20.

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.

Guglielmelli P, Biamonte F, Rotunno G, Artusi V, Artuso L, Bernardis I, Tenedini E, Pieri L, Paoli C, Mannarelli C, Fjerza R, Rumi E, Stalbovskaya V, Squires M, Cazzola M, Manfredini R, Harrison C, Tagliafico E, Vannucchi AM; COMFORT-II Investigators; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators.

Blood. 2014 Apr 3;123(14):2157-60. doi: 10.1182/blood-2013-11-536557. Epub 2014 Jan 23.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk